• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pyxis Oncology, Inc. - Common Stock (NQ: PYXS )

    1.600 -0.070 (-4.19%)
    Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 712,764
    Open 1.670
    Bid (Size) 1.590 (1)
    Ask (Size) 1.600 (21)
    Prev. Close 1.670
    Today's Range 1.570 - 1.670
    52wk Range 1.490 - 6.850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
    Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
    Via Benzinga
    Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
    From Pyxis Oncology
    Via GlobeNewswire

    Performance

    YTD
    -22.33%
    -22.33%
    1 Month
    -15.34%
    -15.34%
    3 Month
    -55.56%
    -55.56%
    6 Month
    -47.71%
    -47.71%
    1 Year
    -8.05%
    -8.05%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
    Via Benzinga
    Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
    Via Benzinga
    Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
    Via Benzinga
    Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    From Pyxis Oncology
    Via GlobeNewswire
    PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
    Via InvestorPlace
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
    From Pyxis Oncology
    Via GlobeNewswire
    Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    From Pyxis Oncology
    Via GlobeNewswire
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Exposures Glyphosate
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Pyxis Oncology
    Via GlobeNewswire
    3 Biotech Stocks to Buy on the Dip: March 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.